BiotechTube

Hepatitis C Immune Globulin Intravenous (Human) 5%

Phase 2Terminated
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sequelae of Viral Hepatitis

Conditions

Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation

Trial Timeline

May 1, 2007 → Feb 1, 2009

NCT ID
NCT00473824

About Hepatitis C Immune Globulin Intravenous (Human) 5%

Hepatitis C Immune Globulin Intravenous (Human) 5% is a phase 2 stage product being developed by ADMA Biologics for Sequelae of Viral Hepatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00473824. Target conditions include Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00473824Phase 2Terminated

Competing Products

2 competing products in Sequelae of Viral Hepatitis

See all competitors
ProductCompanyStageHype Score
Nirmatrelvir + Placebo + RitonavirPfizerPhase 2
51
TNX-102 SL + Placebo SL TabletTonix PharmaceuticalsPhase 2
44

Other Products from ADMA Biologics

Asceniv™Approved
80
BivigamApproved
80
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]Phase 3
72
RI-002Phase 3
72
RI-001 + RI-001 + RI-001Phase 2
47